What Proportion of Patients Treated With Calcium Phosphate and Calcium Sulfate Bone Substitutes for Benign Pediatric...

Synthetic composites of calcium phosphate and calcium sulfate have been used for grafting after intralesional curettage of benign bone tumors. However, there are limited studies on the outcomes of children who were grafted with these materials.

(1) What proportion of patients with benign pediatric bone lesions who were treated with synthetic calcium phosphate and calcium sulfate bone substitute as a bone void filler experienced radiographic graft resorption by 1 year after treatment? (2) What proportion of patients thus treated experienced recurrence of the tumor or fracture at a minimum follow-up time of 1 year?

Between 2020 and 2023, a total of 42 patients were surgically treated for benign lytic bone tumors or bone cysts at a single tertiary academic children's hospital. Two were excluded from analysis (one because it was a recurrent aneurysmal bone cyst initially treated with curettage and bone grafting, and one who was treated with aspiration and corticosteroid injection of the cyst at the family's request), leaving 40 who were treated with curettage and grafting using synthetic calcium phosphate and calcium sulfate bone substitute. All had at least 12 months of follow-up (mean ± SD 32 ± 15 months) and were analyzed in this retrospective study. Of the patients, 30% (12 of 40) were female, and the mean age of the cohort was 12 ± 4 years. During this time, adjunctive internal fixation hardware was generally used when there was a pathologic fracture, and based on those indications, 23% (9 of 40) received hardware. To answer our first study question about the proportion of lesions that demonstrated graft resorption by 1 year after treatment, we annotated the lesions and assessed for percent resorption at 6 weeks, 12 weeks, 6 months, 9 months, and 12 months. To answer our second study question, we used a Kaplan-Meier survivorship estimator to determine survivorship free from recurrence and survivorship free from fracture.

Eighty-eight percent (35 of 40) developed complete resorption of the graft by 1 year after surgery; 45% (18 of 40) demonstrated this finding by 4 months after surgery. Thirteen percent (5) of patients developed local recurrence. Survivorship free from local recurrence was 88% (95% confidence interval [CI] 77% to 99%) at 1 year, and survivorship free from fracture was 100% (95% CI not estimable) at 1 year. Of those that recurred, there were three aneurysmal bone cysts, one unicameral bone cyst, and one chondroblastoma.

The bone substitute was associated with gradual resorption, low recurrence rates, and no fractures in this cohort. With the right indications, patients can start weightbearing at 6 weeks without hardware augmentation. Close monitoring is crucial, especially for aneurysmal bone cysts that have a higher risk of recurrence. Further research may be needed to compare the effectiveness and cost-efficiency of bone substitutes and alternative graft options.

Level IV, therapeutic study.